Jee Youn Hee, Celi Francesco S, Sampson Maureen, Sacks David B, Remaley Alan T, Kebebew Electron, Baron Jeffrey
Section on Growth and Development, Program on Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA.
Division of Endocrinology and Metabolism, Virginia Commonwealth University, Bethesda, MD, USA.
Clin Endocrinol (Oxf). 2015 Dec;83(6):977-84. doi: 10.1111/cen.12676. Epub 2015 Jan 15.
The primary preoperative method for distinguishing malignant from benign thyroid nodules is fine-needle aspiration (FNA) cytology, but it is frequently inconclusive. Midkine (MDK) is a heparin-binding growth factor, which is overexpressed in papillary thyroid carcinoma (PTC).
We measured MDK concentrations in FNA samples from benign and malignant thyroid nodules to explore the possibility that MDK measurement might aid in the evaluation of thyroid nodules.
35 subjects underwent preoperative FNA of 45 thyroid nodules, followed by thyroidectomy, providing a histological diagnosis. FNA needle contents were first expressed for cytology, and then, the needle was washed with buffer for immunoassay. In 46 subjects without preoperative FNA samples, FNA was performed ex vivo on 62 nodules within surgically excised thyroid tissue.
MDK was measured using a high-sensitivity sandwich ELISA and normalized to thyroglobulin (Tg) concentration in the sample to adjust for tissue content in the aspirate.
The MDK/Tg ratio was higher in 18 PTCs than in 87 benign nodules (204 ± 106 vs 1·2 ± 0·3 ng/mg, mean ± SEM, P < 0·001). Using a threshold of 10 ng/mg, the sensitivity and specificity of the MDK/Tg ratio for diagnosis of PTC were 67% and 99%, respectively. All follicular variant PTCs had a MDK/Tg ratio <10 ng/mg.
The findings indicate that, in FNA samples, the MDK/Tg ratio in PTC is greater than in benign thyroid nodules, raising the possibility that this approach might provide adjunctive diagnostic or prognostic information to complement existing approaches.
术前区分甲状腺恶性结节与良性结节的主要方法是细针穿刺(FNA)细胞学检查,但结果常常不明确。中期因子(MDK)是一种肝素结合生长因子,在甲状腺乳头状癌(PTC)中过表达。
我们测定了来自良性和恶性甲状腺结节的FNA样本中的MDK浓度,以探讨MDK测定有助于评估甲状腺结节的可能性。
35名受试者对45个甲状腺结节进行了术前FNA,随后进行甲状腺切除术,以获得组织学诊断。FNA针内的物质首先用于细胞学检查,然后用缓冲液冲洗针以进行免疫测定。在46名没有术前FNA样本的受试者中,对手术切除的甲状腺组织内的62个结节进行了离体FNA。
使用高灵敏度夹心ELISA法测定MDK,并将其标准化为样本中的甲状腺球蛋白(Tg)浓度,以校正抽吸物中的组织含量。
18例PTC的MDK/Tg比值高于87个良性结节(204±106对1.2±0.3 ng/mg,平均值±标准误,P<0.001)。以10 ng/mg为阈值,MDK/Tg比值诊断PTC的敏感性和特异性分别为67%和99%。所有滤泡变异型PTC的MDK/Tg比值均<10 ng/mg。
研究结果表明,在FNA样本中,PTC的MDK/Tg比值高于良性甲状腺结节,这增加了这种方法可能提供辅助诊断或预后信息以补充现有方法的可能性。